Loading viewer...
investor_presentation
Format: PDF investor_presentation
Teva Pharmaceutical Industries Ltd. Second Quarter 2017 Results August 3, 2017
Teva Pharmaceutical Industries Ltd.
Second Quarter 2017 Results
Cautionary Note Regarding Forward -Looking Statements
This presentation contains forward -looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 , which are based on management’s current beliefs and expectations and are subject to
substantial risks and uncertainties, both known and unknown, that could cause our future results, performance or achievements to differ significantly from that expressed or implied by such forward -looking statements .
Important factors that could cause or contribute to such differences include risks relating to:
• our generics medicines business, including : that we are substantially more dependent on this business, with its significant attendant risks, following our acquisition of Allergan plc’s worldwide generic
pharmaceuticals business (“Actavis Generics”) ; our ability to realize the anticipated benefits of the acquisition (and any delay in realizing those benefits) or difficulties in integrating Actavis Generics ; the increase in the
number of competitors targeting generic opportunities and seeking U.S. market exclusivity for generic versions of significant products ; price erosion relating to our generic products, both from competing products and as a
result of increased governmental pricing pressures ; and our ability to take advantage of high -value biosimilar opportunities ;
• our specialty medicines business, including : competition for our specialty products, especially Copaxone®, our leading medicine, which faces competition from existing and potential additional generic versions
and orally -administered alternatives ; our ability to achieve expected results from investments in our product pipeline ; competition from companies with greater resources and capabilities ; and the effectiveness of our
patents and other measures to protect our intellectual property rights ;
• our substantially increased indebtedness and significantly decreased cash on hand, which may limit our ability to incur additional indebtedness, engage in additional transactions or make new investments, and
may result in a downgrade of our credit ratings ;
• our business and operations in general, including : uncertainties relating to our recent senior management changes ; our ability to develop and commercialize additional pharmaceutical products ; manufacturing
or quality control problems, which may damage our reputation for quality production and require costly remediation ; interruptions in our supply chain, including due to labor unrest; disruptions of our or third party
Preview truncated — download the full document for the complete content.
investor_presentation
37 Pages
investor_presentation
35 Pages
II-VI Incorporated
JBT Corporation Investor Presentation 2023
investor_presentationinvestor_presentation
22 Pages
John Bean Technologies Corporation
Münchener Rückversicherungs-Gesellschaft Investor Presentation — February 2017
investor_presentationinvestor_presentation
12 Pages
Münchener Rückversicherungs-Gesellschaft